Transfusion · 2019 · 12 citations · 9 references
Life SciencesHematologyImmunologyClinical ImmunologyImmunotherapyMonoclonal AntibodiesDonor-specific AntibodiesMonoclonal Antibody TechnologyMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesAntibodiesDaratumumab TherapyMonoclonal Antibody TherapeuticsMonoclonal Antibody-based Assays
BACKGROUND: As CD38 is expressed on red blood cells (RBCs), the plasma of patients on daratumumab (DARA) reacts with the panel cells of pretransfusion tests, masking underlying alloantibodies. The treatment of RBCs with dithiothreitol (DTT) is the most disseminated method to overcome DARA effect on immunohematological tests, but it hampers the identification of potentially harmful antibodies. Our goal was to validate a new strategy, the blockage monoclonal antibody protocol (BMAP), to mitigate the DARA interference on RBCs using anti-CD38 and antihuman globulin. METHODS: Samples of patients receiving DARA were included in the study. Sera were tested using both DTT- and BMAP-treated RBCs, which comprised three steps: 1) titration of monoclonal anti-CD38, 2) treatment of RBCs obtained from donors with anti-CD38, and 3) blockage of anti-CD38-adsorbed RBCs with antihuman globulin. RESULTS: Twenty patients were included in the study. Donor RBCs were treated with anti-CD38 and successfully blocked with antihuman globulin. In 19 patients, DARA-mediated agglutination was eliminated using both DTT- and BMAP-treated RBCs. In one patient, agglutination persisted when tested against the BMAP-treated RBCs, and alloantibodies were identified. Patient samples were mixed with commercial anti-D, -C, -e, -K, -Jka, -Kpb and tested against antigen-positive BMAP-treated RBCs, resulting in detection of these antibodies. CONCLUSION: This study validated a new strategy to minimize the interference of DARA on immunohematological tests. The protocol preserves the integrity of RBC antigens, permitting the detection of antibodies from all blood group systems. The BMAP has potential use in other situations where specific antibodies may interfere with pretransfusion screening.
9
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text
Elena Zocchi, L. Franco, Lucrezia Guida et al. · Biochemical and Biophysical Research Communications · 1993 · 278 citations
Resolving the daratumumab interference with blood compatibility testing
Claudia I. Chapuy, Rachel T. Nicholson, Maria Aguad et al. · Transfusion · 2015 · 238 citations · Full text